Breaking News

Takeda to Invest $30B into U.S. Operations

Joins a league of pharma companies increasing investments in the U.S.

Takeda’s Cambridge, MA global hub.

Takeda is the latest major pharmaceutical company to increase its investments in the U.S. market, partly in response to President Donald Trump’s potential tariffs. The company’s CEO, Christophe Weber, announced on Thursday, during the company’s earnings call, that Takeda will be investing approximately $30 billion into its U.S. operations over the next five years.

“This reflects the fact that the U.S. is the world’s leading market for biopharmaceutical innovation, and I hope that will continue,” Weber remarked.

Other pharmaceutical companies that have announced plans to increase investments in the U.S. in anticipation of potential tariffs on the industry include Gilead, Roche, Novartis, and Johnson & Johnson. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters